US EditionPublished • loading... • Updated
Obesity on decline in US as GLP-1 use skyrockets: Gallup
Gallup's 2025 data show 7.6 million fewer obese adults as GLP-1 drug use doubles to 12.4%, yet diabetes diagnoses rise to a record 13.8% due to lasting risk factors.
- On Tuesday, Gallup published updated 2025 figures showing diabetes diagnoses reached an all-time high of 13.8% while U.S. adult obesity fell to 37%.
- Because diabetes is a lifetime disease, short-term drops in obesity won't immediately lower prevalence, and other risks like physical inactivity, race and ethnicity, and genetic predisposition raise diabetes risk.
- Gallup found 12.4% of adults now report using Type 2 antidiabetic GLP-1 drugs, up from 5.8% in February 2024, from surveys of 16,946 U.S. adults.
- This decline represents about 7.6 million fewer obese adults, with the largest drops among adults aged 40 to 49 and 50 to 64, whose obesity rates fell to 43.3% and 42.8%.
- Policy choices matter: 13 states fully cover GLP-1s under Medicaid, Gallup cautions these drugs are not a cure-all, and teplizumab approved in 2022 recently showed promise amid limited treatment access for people living with diabetes.
Insights by Ground AI
20 Articles
20 Articles
The Needle and the Nation: How Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs are quietly deflating America's wasteline
Explore how GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are impacting obesity rates in America, while also highlighting the challenges of accessibility and socioeconomic disparities.
·India
Read Full Article
Coverage Details
Total News Sources20
Leaning Left8Leaning Right3Center7Last UpdatedBias Distribution44% Left
Bias Distribution
- 44% of the sources lean Left
44% Left
L 44%
C 39%
R 17%
Factuality
To view factuality data please Upgrade to Premium
